Skip to main content
2024 Midyear Clinical Meeting & Exhibition Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Certified Pharmacy Executive Leader
Certified Pharmacy Executive Leader
Digital Health & Informatics
Digital Health & Informatics
Diversity, Equity and Inclusion
Diversity, Equity and Inclusion
Health & Wellness
Health & Wellness
Opioids & Pain Management
Opioids & Pain Management
Sterile Compounding
Sterile Compounding
Back

Educational Sessions

Clinical Pearls 2024

Transitioning the Oral Factor Xa Inhibitor Rivaroxaban to Parenteral Anticoagulation in Acute Kidney Injury

Tuesday, December 10, 2024
2:05 PM – 2:10 PM  
Location: MCCNO, Theater B, Level 2

Learning Objectives:

  • Describe how calibrated anti-xa level monitoring could be implemented for patients with acute kidney injury being anticoagulated with rivaroxaban for transition to parenteral anticoagulation.